Kazakhstan introduces 15-day registration for medicines from high-standard markets

BAKU, Azerbaijan, November 3. Kazakhstan has
introduced an accelerated registration procedure for medicines from
countries with high quality control standards, reducing the
registration period to 15 working days, Minister of Health Akmaral
Alnazarova said at a government meeting.

According to the press service of the Kazakh government, the new
procedure is aimed at expanding patients' access to modern and
innovative medicines.

To date, 16 medicines and medical devices manufactured in the
United States, Germany, France, Denmark, the United Kingdom and the
Republic of Korea have been registered under this procedure.

"We are creating conditions for modern medicines to enter the
Kazakh market more quickly. At the same time, quality and safety
requirements remain our absolute priority. For citizens, this
primarily means access to new treatment methods," Alnazarova
said.

Legislative changes have also introduced a one-stop-shop
principle to simplify registration procedures. More than 600
services have already been provided through the new mechanism.

Since 2026, the country has also allowed the state to initiate
the registration of essential medicines without waiting for an
application from the manufacturer.

Digital technologies, including artificial intelligence, are
being introduced to analyze registration documents and improve the
efficiency of the review process.

Particular attention is being paid to state quality control of
medicines and the development of a system for monitoring adverse
drug reactions.

An important international milestone was the World Health
Organization's confirmation that Kazakhstan's national regulatory
system has reached Maturity Level 3. Kazakhstan became the first
CIS country to achieve this level.

The next stage will involve developing laboratory
infrastructure, including the construction of a modern facility in
Astana to test vaccines and independently assess their quality and
safety.

The measures are aimed at expanding public access to modern
medicines while maintaining strict quality standards.